Source: Annual Congress 2007 - Infectious lung and pleural diseases
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Karchevskaya, M. Koutsenko, A. Chuchalin (Moscow, Russian Federation). Dependence between procalcitonin level and pneumonia risk classes. Eur Respir J 2007; 30: Suppl. 51, 2723

Member's Comments

No comment yet.

Related content which might interest you: Level of serum procalcitonin and pneumonia risk classes Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 groups at risk Source: Eur Respir J 2007; 30: Suppl. 51, 481s Year: 2007 Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia Source: Eur Respir J 2008; 31: 356-362 Year: 2008 Correlation of procalcitonin and CRP in community-acquired pneumonia with CRB-65 score and prognosis – results from the German competence network CAPNETZ Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Predictive value of procalcitonin in ventilator-associated pneumonia Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006 Prognostic value of procalcitonin in community-acquired pneumonia Source: Eur Respir J 2011; 37: 384 Year: 2011 Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Elevated troponin and creatinine levels are associated with higher mortality in community-acquired pneumonia Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Prognostic value of plasma D-dimer level in adults with community-acquired pneumonia – A prospective study Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Incidence of ventilator associated pneumonia (VAP) and assessment of serial estimation of procalcitonin levels as a prognostic marker in cases of VAP in a tertiary centre in India Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections Year: 2012